Abstract |
The use of haplo-HCT with posttransplant cyclophosphamide (PT-Cy) is a new standard in the treatment of hematological diseases. A paucity of data exists on risk factors for engraftment failure in haplo-HCT with PT-Cy. We analyzed 1939 adults with acute myeloid leukemia (AML) who received a first haplo-HCT from 2010 to 2019. Status at haplo-HCT was first complete remission (CR1) in 72.5% of patients, secondary AML was reported in 9.9%. Median follow-up was 24.4 months and median age at haplo-HCT was 51 years. Stem cell source was bone marrow (BM) in 42% and peripheral blood stem cell (PBSC) in 58%, and 64% of patients received a myeloablative conditioning ( MAC) regimen. Cumulative incidence of primary graft failure (GF) was 6%; GF was reported in 110 patients and 54 died before day +30 with no sign of cell recovery. Overall, 33 patients underwent a second HCT in a median time of 45 days and 13 were alive at last follow-up, the 2-year overall survival (OS) after second HCT being 32.4%. In multivariate analysis, factors independently associated with the risk of nonengraftment were: secondary AML (HR 1.30, p = 0.003), use of RIC (HR 1.22, p < 0.001), and use of BM (HR 1.21, p < 0.001). At 2 years, leukemia-free survival (LFS) and OS for the entire population was 55.2% (95% CI: 52.6-57.6) and 60.9% (95% CI: 58.4-63.3), respectively. Incidence of GF after haplo-HCT with PT-Cy is lower than reported T-cell-depleted haplo-HCT. Optimization of conditioning regimen and graft source should be considered for reducing the risk of GF in haplo-HCT recipients using PT-Cy.
|
Authors | Annalisa Ruggeri, Myriam Labopin, Emanuele Angelucci, Didier Blaise, Fabio Ciceri, Yener Koc, Patrizia Chiusolo, Jose Luiz Diez-Martin, Zafer Gülbas, Luca Castagna, Benedetto Bruno, Mutlu Arat, Massimo Martino, Arnon Nagler, Mohamad Mohty |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 56
Issue 8
Pg. 1842-1849
(08 2021)
ISSN: 1476-5365 [Electronic] England |
PMID | 33674790
(Publication Type: Journal Article)
|
Copyright | © 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature. |
Chemical References |
|
Topics |
- Cyclophosphamide
- Graft vs Host Disease
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
(therapy)
- Neutrophils
- Prognosis
- Retrospective Studies
- Transplantation Conditioning
|